Kintara Therapeutics, Inc. (KTRA): Price and Financial Metrics


Kintara Therapeutics, Inc. (KTRA): $6.30

0.26 (+4.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KTRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

KTRA Stock Price Chart Interactive Chart >

Price chart for KTRA

KTRA Price/Volume Stats

Current price $6.30 52-week high $42.00
Prev. close $6.03 52-week low $3.50
Day low $5.91 Volume 40,828
Day high $6.74 Avg. volume 40,780
50-day MA $7.43 Dividend yield N/A
200-day MA $8.61 Market Cap 10.18M

Kintara Therapeutics, Inc. (KTRA) Company Bio


Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.


KTRA Latest News Stream


Event/Time News Detail
Loading, please wait...

KTRA Latest Social Stream


Loading social stream, please wait...

View Full KTRA Social Stream

Latest KTRA News From Around the Web

Below are the latest news stories about KINTARA THERAPEUTICS INC that investors may wish to consider to help them evaluate KTRA as an investment opportunity.

Kintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be presenting at the Biotech Showcase Conference in San Francisco.

Yahoo | January 9, 2023

Kintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma (DIPG), a rare and highly-aggressive childhood brain cancer.

Yahoo | December 15, 2022

10 Pump and Dump Stocks Hedge Funds Like

In this article, we discuss the 10 pump and dump stocks hedge funds like. If you want to read about some more pump and dump stocks, go directly to 5 Pump and Dump Stocks Hedge Funds Like. The influx of retail investors on the stock market in recent months and the rise of social media […]

Yahoo | December 2, 2022

Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Robert E. Hoffman, President and CEO of Kintara, will be participating at the RHK Capital Disruptive Growth Conference in New York City.

Yahoo | December 1, 2022

Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the Company has received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) for continued listing on The Nasdaq Capital Market.

Yahoo | November 30, 2022

Read More 'KTRA' Stories Here

KTRA Price Returns

1-mo -8.56%
3-mo 21.62%
6-mo -42.60%
1-year -69.64%
3-year -76.47%
5-year -99.17%
YTD -8.56%
2022 -72.98%
2021 -60.16%
2020 85.59%
2019 -79.71%
2018 -68.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6901 seconds.